CSL share price (ASX:CSL) rises 6% despite HY22 profit fall
Lachlan Buur-Jensen
February 16, 2022
The CSL Limited (ASX: CSL) share price has stormed out
CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
The CSL Limited (ASX: CSL) share price has stormed out
Your guide to the BHP Group Ltd (ASX:BHP) reunification process
Australian investors had some respite on Friday, as volatility disappeared
I think that investing in ASX shares is the best
The S&P/ASX 200 (ASX: XJO) didn’t follow global markets higher
The S&P/ASX 200 (ASX:XJO) dropped 0.7% on Thursday as Wesfarmers
The S&P/ASX 200 (ASX: XJO) finished broadly flat on Tuesday
CSL Limited (ASX: CSL) has announced a blockbuster US$12.3 billion
The S&P/ASX 200 (ASX: XJO) managed another strong opening on
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
